Trevena Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Trevena stock.
View analyst ratings for Trevena or view top-rated stocks.

Wall Street analysts have given Trevena a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trevena wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Trevena saw a drop in short interest in the month of August. As of August 13th, there was short interest totaling 14,830,000 shares, a drop of 16.0% from the July 29th total of 17,650,000 shares. Based on an average daily volume of 2,250,000 shares, the days-to-cover ratio is presently 6.6 days. Currently, 9.3% of the company's shares are sold short.
View Trevena's Short Interest.

Trevena is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Trevena.

Trevena, Inc. (NASDAQ:TRVN) issued its quarterly earnings results on Thursday, August, 12th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.01. Trevena had a negative net margin of 1,194.62% and a negative trailing twelve-month return on equity of 40.89%.
View Trevena's earnings history.

Trevena's stock was trading at $0.6984 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TRVN stock has increased by 79.0% and is now trading at $1.25.
View which stocks have been most impacted by COVID-19.

2 brokerages have issued 12-month target prices for Trevena's stock. Their forecasts range from $6.00 to $6.00. On average, they expect Trevena's stock price to reach $6.00 in the next year. This suggests a possible upside of 380.0% from the stock's current price.
View analysts' price targets for Trevena or view top-rated stocks among Wall Street analysts.

Some companies that are related to Trevena include Dyne Therapeutics (DYN), Annexon (ANNX), Kiniksa Pharmaceuticals (KNSA), Akero Therapeutics (AKRO), VBI Vaccines (VBIV), Crinetics Pharmaceuticals (CRNX), Shattuck Labs (STTK), BioXcel Therapeutics (BTAI), Gossamer Bio (GOSS), Celularity (CELU), Ocular Therapeutix (OCUL), Cara Therapeutics (CARA), Amryt Pharma (AMYT), AnaptysBio (ANAB) and PyroGenesis Canada (PYR).
View all of TRVN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX).

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Trevena's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.79%), Vanguard Group Inc. (4.68%), Geode Capital Management LLC (1.65%), State Street Corp (1.62%), Northern Trust Corp (0.35%) and Nuveen Asset Management LLC (0.34%).
View institutional ownership trends for Trevena.

TRVN stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Cubist Systematic Strategies LLC, Citadel Advisors LLC, Goldman Sachs Group Inc., Group One Trading L.P., Jacobi Capital Management LLC, and Wells Fargo & Company MN.
View insider buying and selling activity for Trevena or view top insider-selling stocks.

TRVN stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Geode Capital Management LLC, Vanguard Group Inc., Nuveen Asset Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., and Northern Trust Corp.
View insider buying and selling activity for Trevena or or view top insider-buying stocks.

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TRVN stock can currently be purchased for approximately $1.25.

Trevena has a market capitalization of $205.64 million and generates $3.07 million in revenue each year. The biopharmaceutical company earns $-29,370,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.

Trevena employs 25 workers across the globe.

The official website for Trevena is www.trevena.com.

Trevena is headquartered at 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087.

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at [email protected].